Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
AMSTERDAM, the Netherlands, Jan. 6, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company's management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.
The conference call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code: 1640435. The webcast, including accompanying slides also available as a PDF file, can be accessed through the link displayed in the "Events" section on the "Media" page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/. The webcast replay will be available for at least 72 hours following the call.
Conference Call Numbers
| London, United Kingdom: | +44 (0) 20 3427 1906 | |
| New York, United States of America: | +1 212 444 0412 | |
| Berlin, Germany: | +49 (0) 30 3001 90534 | |
| Amsterdam, Netherlands: | +31 (0) 20 716 8296 | |
| Paris, France: | +33 (0) 1 76 77 22 31 | |
| Milan, Italy: | +39 02 3859 1420 | |
| Brussels, Belgium: | +32 (0) 2 402 3092 | |
| Montreal, Canada: | +1 514 841 2154 | |
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Direct: +31 20 240 6110
Main: +31 20 240 6000
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or
+1 781 235 3060
[email protected]
